Exscentia develops sixth molecule to be assessed in psychiatric created through AI

By Liza Laws

- Last updated on GMT

Related tags Artificial intelligence Drug discovery AI Clinical trial Pharmaceutical industry

Exscientia plc has announced a sixth molecule has been created through its generative artificial intelligence (AI) platform to enter clinical stage. It is the third clinical molecule from a collaboration with Sunitomo Pharma to enter phase 1 trials.

The company's founder and CEO,Andrew Hopkins, has said he believes that ‘all new therapies will be designed with the help of AI in the future.’

Hopkins announced yesterday (May 15) that Sumitomo Pharma Co., Ltd. plans to initiate a phase 1 clinical study of DSP-2342 in the United States.

DSP-2342 is a highly selective bispecific small molecule with potent dual 5-HT2A and 5-HT7 antagonist activity with broad potential in psychiatric disease.

It is the third molecule created using Exscientia’s AI-driven drug discovery platform under a collaboration with Sumitomo, referred to as design as a service or DaaS.

Hopkins said: “Using AI, we are creating a much more efficient process to design and develop differentiated drug candidates. We believe that all new therapies will be designed with the help of AI in the future.”

“With three AI-generated development compounds designed for Sumitomo Pharma, plus our own emerging pipeline, we have repeatedly validated our approach and are on track to achieve our vision of encoding and automating pharmaceutical R&D.

Following the successful conclusion of the DaaS partnership for DSP-2342, Sumitomo holds all further development, commercial and economic rights to the compound.

However, Exscientia maintains ownership of or economic rights to all compounds in its portfolio outside of the original Sumitomo Pharma agreement.

These include EXS21546, an A2A receptor antagonist, GTAEXS617, a CDK7 inhibitor and EXS4318, a selective PKC-theta inhibitor being evaluated in inflammatory diseases by Bristol Myers Squibb.

In addition, two further wholly owned precision oncology development candidates, EXS74539, an LSD1 inhibitor and EXS73565, a MALT1 protease inhibitor, have been announced recently and are currently progressing through IND/CTA-enabling studies.

Exscientia is an AI-driven precision medicine company committed to discovering, designing and says its aim is developing the best possible drugs in the fastest and most effective manner.

The company developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting.

Exscientia says its internal pipeline is focused on leveraging its precision medicine platform in oncology, while their partnered pipeline broadens their approach to other therapeutic areas.

Related news

Related product

A Guide Through the API Drug Development Pipeline.

A Guide Through the API Drug Development Pipeline.

Content provided by Lonza Small Molecules | 04-Apr-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Related suppliers

Follow us


View more